Zepbound 7.5 mg/0.5 mL Pen

Description

Zepbound 7.5 mg/0.5 mL Pen is a mid-tier maintenance dose designed for adults progressing in their weight loss journey. It delivers a dual-hormone formulation of tirzepatide, helping regulate appetite and metabolism more powerfully than earlier doses. This once-weekly injection continues to enhance fat loss while promoting better glycemic control and long-term weight management.

💊 Key Features of Zepbound 7.5 mg/0.5 mL Pen

• Contains 7.5 mg of tirzepatide in a 0.5 mL single-dose pen

• Administered once weekly under the skin (subcutaneous)

• Dual GLP-1 and GIP agonist for synergistic metabolic effects

• Prefilled pen with auto-injection – no mixing or needles required

• Ideal for continued treatment after tolerating lower doses

📦 What’s Included

• Available in packs of 1 or 4 single-use pens (7.5 mg/0.5 mL)

• Prefilled, ready-to-inject devices with easy push-button delivery

• Step-by-step usage instructions included

🌟 Clinical Benefits

• Enhances feelings of fullness and reduces food cravings

• Supports sustainable and clinically meaningful weight loss

• May improve blood sugar control in adults with type 2 diabetes

• Allows for continued, personalized dose titration as prescribed

🩺 Dosage & Usage Guidelines

• Inject once a week, same day each week (with or without meals)

• Rotate injection sites between abdomen, thigh, or upper arm

• Use 7.5 mg weekly for at least 4 weeks or as directed by your healthcare provider

• Do not reuse pens – discard safely after each dose

⚠️ Important Safety Information

• Contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN 2

• Common side effects: nausea, diarrhea, vomiting, constipation

• Rare but serious risks: pancreatitis, gallbladder issues, kidney problems, allergic reactions

• Not intended for use with other GLP-1 receptor agonists

• Always consult your healthcare provider before increasing your dosage

❄️ Storage Instructions

• Store in refrigerator at 36°F to 46°F (2°C to 8°C)

• May be kept at room temperature (≤86°F / 30°C) for up to 21 days

• Do not freeze or expose to direct sunlight or heat

• Dispose of used pens in a sharps container

❓ Frequently Asked Questions

Q: Is 7.5 mg stronger than the starter doses?
A: Yes. It’s intended for patients who have tolerated and completed the 2.5 mg and 5 mg phases.

Q: Will I lose more weight at this dose?
A: Many patients continue to see significant weight loss progression with 7.5 mg as part of a step-up strategy.

Q: Can I stay at 7.5 mg long-term?
A: Yes, depending on your weight loss goals and how your body responds. Your doctor will guide any adjustments.

Q: How should I dispose of used pens?
A: Place them in a puncture-resistant sharps container. Do not throw them directly into household trash.

Q: Are Zepbound and Mounjaro the same
A: Mounjaro and Zepbound are brand names for the same drug, tirzepatide. While Mounjaro is approved for type 2 diabetes, Zepbound is approved for weight management in adults with a BMI of 30 or more. It’s also approved if you’re overweight and have another health condition including: High blood pressure.

Q: Can Zepbound cause anxiety?
A: Although it is not reported in clinical trials of Zepbound. However, this side effect occurred in clinical trials of weight loss drugs similar to Zepbound. Symptoms can include: mood changes agitation and restlessness worsening anxiety or panic attacks depression

Q: Who makes Zepbound?
A: Zepbound (tirzepatide) is manufactured by Eli Lilly and Company, a global pharmaceutical firm headquartered in Indianapolis, Indiana. Eli Lilly is also the maker of Mounjaro, another medication that uses the same active ingredient, tirzepatide. Zepbound was specifically developed and approved by the FDA for weight loss and chronic weight management, distinguishing it from Mounjaro, which was originally approved for type 2 diabetes. With decades of experience in producing trusted medications, Eli Lilly continues to be a leader in innovative treatments for both metabolic and chronic conditions.